Pacira BioSciences, Inc. Common Stock (PCRX) Stock Price

PCRXStock

$36.34+59.60%52W

Market Cap$1.45B

P/E205.94x

PEG Ratio0.99

Div yield—

Beta0.24

PCRX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)43.10%

Price vs S&P 500 (4W)52.05%

PEG Ratio0.99

VGM Score64.07

P/E Ratio (Annual)205.94x

P/CF (Annual)9.53x

Book Value / Share (Quarterly)$16.87

P/TBV (Annual)3.43x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)2.90%

Cash Flow / Share (Quarterly)$4.51

Price vs S&P 500 (YTD)28.49%

Gross Margin (TTM)79.21%

Net Profit Margin (TTM)1.96%

EPS (TTM)$0.35

10-Day Avg Trading Volume4.50M

EPS Excl Extra (TTM)$0.35

Revenue Growth (5Y)11.08%

EPS (Annual)$0.16

ROI (Annual)0.66%

Gross Margin (Annual)79.39%

Net Profit Margin (5Y Avg)0.63%

Cash / Share (Quarterly)$6.30

P/E Basic Excl Extra (TTM)98.96x

Revenue Growth QoQ (YoY)6.24%

EPS Growth (5Y)-45.77%

P/E Normalized (Annual)205.94x

ROA (Last FY)0.56%

Revenue Growth TTM (YoY)5.71%

EBITD / Share (TTM)$1.55

ROE (5Y Avg)0.17%

Operating Margin (TTM)1.06%

Cash Flow / Share (Annual)$3.32

P/B Ratio2.16x

P/B Ratio (Quarterly)1.49x

Net Income / Employee (Annual)$8,500

EV / Revenue (TTM)2.15x

Net Interest Coverage (TTM)7.96x

ROA (TTM)1.17%

EPS Growth QoQ (YoY)-31.04%

EV / EBITDA (TTM)24.64x

EPS Incl Extra (Annual)$0.16

Current Ratio (Annual)4.54x

Quick Ratio (Quarterly)3.69x

3-Month Avg Trading Volume1.00M

52-Week Price Return59.60%

EV / Free Cash Flow (Annual)11.75x

P/E Incl Extra (TTM)98.96x

Revenue / Employee (TTM)$900,100

Tangible BV / Share (Quarterly)$9.71

P/S Ratio (Annual)1.99x

Asset Turnover (Annual)0.57x

52-Week High$36.66

Operating Margin (5Y Avg)5.54%

EPS Excl Extra (Annual)$0.16

CapEx CAGR (5Y)-16.51%

Tangible BV CAGR (5Y)-9.08%

26-Week Price Return53.01%

Quick Ratio (Annual)3.01x

13-Week Price Return41.90%

Total Debt / Equity (Annual)0.54x

Current Ratio (Quarterly)5.04x

Enterprise Value$1.61B

Revenue / Share Growth (5Y)10.41%

Asset Turnover (TTM)0.60x

Book Value / Share Growth (5Y)3.47%

Revenue / Employee (Annual)$876,200

Inventory Turnover (Annual)1.08x

Pretax Margin (Annual)2.32%

Cash / Share (Annual)$5.80

3-Month Return Std Dev93.86%

Gross Margin (5Y Avg)74.39%

Net Income / Employee (TTM)$17,700

EBITDA CAGR (5Y)6.90%

EBITDA Interim CAGR (5Y)-12.77%

ROE (Last FY)1.01%

Net Interest Coverage (Annual)2.61x

EPS Basic Excl Extra (Annual)$0.16

P/FCF (TTM)8.07x

Receivables Turnover (TTM)6.05x

EV / Free Cash Flow (TTM)8.95x

Total Debt / Equity (Quarterly)0.54x

EPS Incl Extra (TTM)$0.35

Receivables Turnover (Annual)6.12x

ROI (TTM)1.39%

P/S Ratio (TTM)1.94x

Pretax Margin (5Y Avg)2.97%

Revenue / Share (Annual)$16.13

Tangible BV / Share (Annual)$7.90

Forward P/E7.55x

Free OCF CAGR (5Y)28.37%

Price vs S&P 500 (52W)44.06%

P/E Ratio (TTM)98.96x

Year-to-Date Return40.42%

5-Day Price Return-0.03%

EPS Normalized (Annual)$0.16

ROA (5Y Avg)-0.04%

Net Profit Margin (Annual)0.97%

Month-to-Date Return45.07%

Cash Flow / Share (TTM)$1.93

EBITD / Share (Annual)$1.43

EPS Growth (3Y)-22.98%

Operating Margin (Annual)0.99%

LT Debt / Equity (Annual)0.54x

P/CF (TTM)7.72x

ROI (5Y Avg)-0.04%

P/E Excl Extra (TTM)98.96x

LT Debt / Equity (Quarterly)0.54x

EPS Basic Excl Extra (TTM)$0.35

P/TBV (Quarterly)2.58x

P/B Ratio (Annual)1.61x

Inventory Turnover (TTM)1.10x

Pretax Margin (TTM)2.37%

Book Value / Share (Annual)$16.86

Price vs S&P 500 (13W)39.21%

Net Margin Growth (5Y)-50.86%

Beta0.24x

P/FCF (Annual)10.60x

Revenue / Share (TTM)$18.52

ROE (TTM)2.13%

52-Week Low$18.80

vGradeC

gGradeC

mGradeA

vgmGradeB

PCRX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 4, 2026	$0.65	$0.73	+12.79%(+$0.08)
Q1 2026	Apr 30, 2026	$0.56	$0.60	+6.41%(+$0.04)
Q4 2025	Feb 26, 2026	$0.90	$0.57	-36.98%(-$0.33)
Q3 2025	Nov 6, 2025	$0.65	$0.70	+7.44%(+$0.05)
Q2 2025	Aug 5, 2025	$0.71	$0.74	+4.18%(+$0.03)

PCRX Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

3.85

3.83

3.85

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
PCRXPacira BioSciences, Inc. Common Stock	C	C	A	1.9x	5.7%	79.2%	-45.8%	$36.34
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Pacira BioSciences, Inc. Common Stock

Pacira BioSciences develops and commercializes non-opioid pain management and regenerative health solutions. The company's marketed products include EXPAREL for postsurgical pain management, ZILRETTA for osteoarthritis, and iovera, a handheld device providing drug-free pain relief through controlled cold therapy. Pacira is also advancing PCRX-201, a gene therapy candidate for knee osteoarthritis.

PCRX Next Earnings Report

Report dateNov 5, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate$0.73

Revenue estimate$182.86M

Also reporting on Nov 5, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

PCRX Insider Transactions

SellAug 17, 2026
SLONIN JONATHAN
Officer
Shares: 3,040Value: $70,619

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for August 2026

Companies in Related Industries

NTLAIntellia Therapeutics, IncIn Vitro Diagnostics
MAZEMaze Therapeutics, Inc. Common StockBiological Products
IMCRImmunocore Holdings plc American Depositary SharesBiological Products
HUNHuntsman CorporationChemicals
SCLStepan Co.Soap & Detergents
COAGHemab Therapeutics Holdings, Inc. Common StockBiological Products
REXREX American Resources Corp.Industrial Chemicals
UANCVR Partners, LPAgricultural Chemicals

Same SIC sector, outside this company's own industry.

Analyst Sentiment

3.9

Buy

Consensus rating

52-Week Range

Low$18.80

High$36.66